ADAPTIVE BIOTECHNOLOGIES news, videos and press releases
For more news please use our advanced search feature.
ADAPTIVE BIOTECHNOLOGIES - More news...
ADAPTIVE BIOTECHNOLOGIES - More news...
- Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025
- Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma
- Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma
- Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results
- Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
- Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
- Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
- Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025
- Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
- Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
- Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
- Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
- Adaptive Announces IVDR Certification for clonoSEQ® in European Union
- Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results
- Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
- Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
- Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
- Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
- Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
- Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
- Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
- Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
- Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
- Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
- Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
- Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update
